Beruflich Dokumente
Kultur Dokumente
Nur 239
Jean Marie Osborne DNP, RN, ANP-C
REQUIRED TEXTS
DIVISION POLICY
AND
UNDERGRADUATE
HANDBOOK
Grading Criteria
• Examinations……………………………. 40%
• Homework…………..…………………. 10%
• 2 Math Quizzes………………………… 10%
• Final Exam………………………………… 35%
• Communicating Across the
Curriculum………………………………… 5%
_______
100%
Laboratory/Skills Requirements
• 2 Skills Modules:
• Re-takes
Chemical Characteristics
– Adrenergics
– Benzodiazepines
Drug Classifications
• Drugs are classified according to their effects
on particular body systems, their therapeutic
uses, and their chemical characteristics.
• Example: Morphine
– CNS depressant
– Narcotic
– Opioid analgesic
Nurses Role in Drug Research
• Drug research involves
risk and is estimated to
cost $800 million on
average to develop each
new drug.
• Drug studies take place
in a variety of inpatient
and outpatient settings.
Basic Ethical Principles
• Four basic ethical principles • The principles of respect for
are relevant to research persons, beneficence, justice,
involving human subjects: and truth telling are integral to
– Respect for persons: client’s the issues of informed consent
choice should be honored and risk-to-benefit ratio in
whenever possible research involving human
• Autonomy- right of self subjects
determination, refuse meds,
refuse research and may
withdraw at any time without
penalty.
– Beneficence-is the duty to not
harm others, to maximize
benefits, and minimize harm
– Justice: all people treated fairly,
equal access to healthcare for
all
– Truth telling: whole truth
Basic Ethical Principles
Informed Consent Risk to Benefit Ratio
• 2 aspects: • IRB determine that “risks to
– Participant’s right to be subjects are reasonable in
informed
relation to anticipated
– Participation is voluntary
benefits, if any, to subjects”
• It is the role of the
healthcare provider, not the • All possible consequences
nurse, to explain the study of a clinical study must be
and to respond to questions analyzed and balanced with
• ***It is the nurse’s role to inherent risks and the
protect clients from any anticipated benefits.
anticipated harm***
Phases of Human Clinical
Experimentation
• Phase I : trials are primarily designed to assess
safety, determine human dosage, identify
pharmacokinetics, assess for serious adverse
effects. (Healthy volunteers). n= 30
• Phase II : demonstrate the safety and efficacy of
the drug in subjects who have the disease the
drug is designed to treat. N=100
• Phase III and IV: involve large numbers of subjects
with the disease intended for treatment.
Demonstrate the safety and efficacy long term
n= 1,000-3,000.
Study Designs
• Controlled treatment groups in drug research trials can
receive no drug; a different drug; a placebo, or the same
drug- different dose, route or frequency.
• Open label study: all parties know the treatment group
assignment.
• Single blind: only the subjects are unaware of which group
they are assigned.
• Double blind: neither the HCP nor the subject knows
whether the subject is receiving the experimental or
control form of therapy.
• Triple blind: a HCP collects data and is also unaware of the
subject’s treatment group therefore removing all biases.
Placebo Effect